|
1
|
Goldhirsch A, Wood WC, Coates AS, et al:
Panel members: Strategies for subtypes - dealing with the diversity
of breast cancer: highlights of the St. Gallen International Expert
Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann
Oncol. 22:1736–1747. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Milde-Langosch K, Karn T, Müller V, et al:
Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in
molecular subgroups of breast cancer. Breast Cancer Res Treat.
137:57–67. 2013. View Article : Google Scholar
|
|
4
|
Wirapati P, Sotiriou C, Kunkel S, et al:
Meta-analysis of gene expression profiles in breast cancer: toward
a unified understanding of breast cancer subtyping and prognosis
signatures. Breast Cancer Res. 10:R652008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bilir A, Ozmen V, Kecer M, et al:
Thymidine labeling index: prognostic role in breast cancer. Am J
Clin Oncol. 27:400–406. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garcia RL, Coltrera MD and Gown AM:
Analysis of proliferative grade using anti-PCNA/cyclin monoclonal
antibodies in fixed, embedded tissues. Comparison with flow
cytometric analysis. Am J Pathol. 134:733–739. 1989.PubMed/NCBI
|
|
7
|
Ignatiadis M and Sotiriou C: Understanding
the molecular basis of histologic grade. Pathobiology. 75:104–111.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stuart-Harris R, Caldas C, Pinder SE and
Pharoah P: Proliferation markers and survival in early breast
cancer: a systematic review and meta-analysis of 85 studies in
32,825 patients. Breast. 17:323–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gerdes J, Schwab U, Lemke H and Stein H:
Production of a mouse monoclonal antibody reactive with a human
nuclear antigen associated with cell proliferation. Int J Cancer.
31:13–20. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gerdes J, Lemke H, Baisch H, et al: Cell
cycle analysis of a cell proliferation-associated human nuclear
antigen defined by the monoclonal antibody Ki-67. J Immunol.
133:1710–1715. 1984.PubMed/NCBI
|
|
11
|
Scholzen T and Gerdes J: The Ki-67
protein: from the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM
and Gelmon KA: Ki67 in breast cancer: prognostic and predictive
potential. Lancet Oncol. 11:174–183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luporsi E, André F, Spyratos F, et al:
Ki-67: level of evidence and methodological considerations for its
role in the clinical management of breast cancer: analytical and
critical review. Breast Cancer Res Treat. 132:895–915. 2012.
View Article : Google Scholar :
|
|
15
|
de Azambuja E, Cardoso F, de Castro G Jr,
et al: Ki-67 as prognostic marker in early breast cancer: a
meta-analysis of published studies involving 12,155 patients. Br J
Cancer. 96:1504–1513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lester SC, Bose S, Chen YY, Connolly JL,
de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page
DL, et al: Members of the Cancer Committee, College of American
Pathologists: Protocol for the examination of specimens from
patients with invasive carcinoma of the breast. Arch Pathol Lab
Med. 133:1515–1538. 2009.PubMed/NCBI
|
|
17
|
Goldhirsch A, Winer EP, Coates AS, et al:
Panel members: Personalizing the treatment of women with early
breast cancer: highlights of the St. Gallen International Expert
Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann
Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ozmen V: Breast Cancer in the World and
Turkey. J Breast Health. 4:7–12. 2008.
|
|
20
|
McShane LM, Altman DG, Sauerbrei W, et al:
Statistics Subcommittee of NCI-EORTC Working Group on Cancer
Diagnostics: REporting recommendations for tumor MARKer prognostic
studies (REMARK). Breast Cancer Res Treat. 100:229–235. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dowsett M, Nielsen TO, A’Hern R, et al:
International Ki-67 in Breast Cancer Working Group: Assessment of
Ki67 in breast cancer: recommendations from the International Ki67
in Breast Cancer Working Group. J Natl Cancer Inst. 103:1656–1664.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hammond ME, Hayes DF, Dowsett M, et al:
American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for immunohistochemical
testing of estrogen and progesterone receptors in breast cancer
(unabridged version). Arch Pathol Lab Med. 134:e48–e72.
2010.PubMed/NCBI
|
|
23
|
Wolff AC, Hammond ME, Schwartz JN, et al:
American Society of Clinical Oncology; College of American
Pathologists: American Society of Clinical Oncology/College of
American Pathologists guideline recommendations for human epidermal
growth factor receptor 2 testing in breast cancer. Arch Pathol Lab
Med. 131:18–43. 2007.
|
|
24
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 19:403–410. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fisher ER, Redmond C and Fisher B:
Histologic grading of breast cancer. Pathol Annu. 15:239–251.
1980.PubMed/NCBI
|
|
26
|
Couris CM, Polazzi S, Olive F, et al:
Breast cancer incidence using administrative data: correction with
sensitivity and specificity. J Clin Epidemiol. 62:660–666. 2009.
View Article : Google Scholar
|
|
27
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hafeez F, Neboori HJ, Harigopal M, et al:
Is Ki-67 expression prognostic for local relapse in early-stage
breast cancer patients treated with breast conservation therapy
(BCT)? Int J Radiat Biol Phys. 87:344–348. 2013. View Article : Google Scholar
|
|
29
|
Lin CH, Liau JY, Lu YS, et al: Molecular
subtypes of breast cancer emerging in young women in Taiwan:
evidence for more than just westernization as a reason for the
disease in Asia. Cancer Epidemiol Biomarkers Prev. 18:1807–1814.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Adebamowo CA, Famooto A, Ogundiran TO, et
al: Immunohistochemical and molecular subtypes of breast cancer in
Nigeria. Breast Cancer Res Treat. 110:183–188. 2008. View Article : Google Scholar
|
|
31
|
Ihemelandu CU, Leffall LD Jr, Dewitty RL,
et al: Molecular breast cancer subtypes in premenopausal and
postmenopausal African-American women: age-specific prevalence and
survival. J Surg Res. 143:109–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nichols HB, Trentham-Dietz A, Love RR, et
al: Differences in breast cancer risk factors by tumor marker
subtypes among premenopausal Vietnamese and Chinese women. Cancer
Epidemiol Biomarkers Prev. 14:41–47. 2005.PubMed/NCBI
|
|
33
|
Akiyama F and Iwase H: Triple negative
breast cancer: clinicopathological characteristics and treatment
strategies. Breast Cancer. 16:252–253. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alli E, Sharma VB, Sunderesakumar P and
Ford JM: Defective repair of oxidative dna damage in
triple-negative breast cancer confers sensitivity to inhibition of
poly (ADP-ribose) polymerase. Cancer Res. 69:3589–3596. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bouchalova K, Cizkova M, Cwiertka K,
Trojanec R and Hajduch M: Triple negative breast cancer - current
status and prospective targeted treatment based on HER1 (EGFR),
TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky
Olomouc Czech Repub. 153:13–17. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carey LA, Dees EC, Sawyer L, et al: The
triple negative paradox: primary tumor chemosensitivity of breast
cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Inwald EC, Klinkhammer-Schalke M,
Hofstädter F, et al: Ki-67 is a prognostic parameter in breast
cancer patients: results of a large population-based cohort of a
cancer registry. Breast Cancer Res Treat. 139:539–552. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nishimura R, Osako T, Okumura Y, et al:
Ki-67 as a prognostic marker according to breast cancer subtype and
a predictor of recurrence time in primary breast cancer. Exp Ther
Med. 1:747–754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
DeCensi A, Guerrieri-Gonzaga A, Gandini S,
et al: Prognostic significance of Ki-67 labeling index after
short-term presurgical tamoxifen in women with ER-positive breast
cancer. Ann Oncol. 22:582–587. 2011. View Article : Google Scholar
|
|
40
|
Aleskandarany MA, Green AR, Rakha EA, et
al: Growth fraction as a predictor of response to chemotherapy in
node-negative breast cancer. Int J Cancer. 126:1761–1769. 2010.
|
|
41
|
Tanei T, Shimomura A, Shimazu K, et al:
Prognostic significance of Ki-67 index after neoadjuvant
chemotherapy in breast cancer. Eur J Surg Oncol. 37:155–161. 2011.
View Article : Google Scholar
|
|
42
|
Munzone E, Botteri E, Sciandivasci A, et
al: Prognostic value of Ki-67 labeling index in patients with
node-negative, triple-negative breast cancer. Breast Cancer Res
Treat. 134:277–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Aleskandarany MA, Green AR, Benhasouna AA,
et al: Prognostic value of proliferation assay in the luminal,
HER2-positive, and triple-negative biologic classes of breast
cancer. Breast Cancer Res. 14:R32012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pathmanathan N and Balleine RL: Ki67 and
proliferation in breast cancer. J Clin Pathol. 66:512–516. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cheang MC, Chia SK, Voduc D, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
